Outcomes associated with initiation of different controller therapies in a medicaid asthmatic population: A retrospective data analysis

Journal of Asthma

Volumn 42, Issue 1, 2005, Pages 35-40

  Balkrishnan, Rajesh ^a   Nelsen, Linda M ^b   Kulkarni, Amit S ^a   Pleasants, Roy A ^c,d   Whitmire, J Timothy ^e   Schechter, Michael S ^f  

^a OHIO STATE UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c DUKE UNIVERSITY   (United States)

^d Campbell University   (United States)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

^f RHODE ISLAND HOSPITAL   (United States)

Author keywords

Asthma; Claims data; Cost analyses; Inhaled corticosteroids; Leukotriene modifiers; Long acting agonists; Medicaid; Retrospective analysis

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; MONTELUKAST; SALMETEROL;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; COST OF ILLNESS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY;

ACETATES; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MEDICAID; PATIENT COMPLIANCE; QUINOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 14944357686     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.1081/JAS-200044769     Document Type: Article

References (24)

1. Pappas G, Hadden WC, Kozak LJ, Fisher GF. Potentially avoidable hospitalizations: inequalities in rates between US socioeconomic groups. Am J Public Health 1997; 87(5):811-816.
2. Gergen PJ, Weiss KB. Changing patterns of asthma hospitalization among children: 1979 to 1987. JAMA 1990; 264(13):1688-1692.
3. Wissow LS, Gittelsohn AM, Szklo M, Starfield B, Mussman M. Poverty, race, and hospitalization for childhood asthma. Am J Public Health 1988; 78(7):777-782.
4. Carr W, Zeitel L, Weiss K. Variations in asthma hospitalizations and deaths in New York City. Am J Public Health 1992; 82(1):59-65.
5. Lozano P, Connell FA, Koepsell TD. Use of health services by African-American children with asthma on Medicaid. JAMA 1995; 274(6):469-473.
6. Balkrishnan R, Norwood GJ, Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients. Clin Ther 1998; 20(3):567-580.
7. Balkrishnan R, Norwood GJ, Anderson A. Outcomes and cost benefit associated with introduction of inhaled corticosteroid therapy in a medicaid enrolled asthmatic children. Drug Benefit Trends 1998; 10(10):37-40.
8. Smith MJ, Rascati KL, Johnsrud MT. Costs and utilization patterns associated with persistent asthma. A comparison of Texas Medicaid patients with and without continuous inhaled corticosteroid treatment. J Manag Care Pharm 2001; 7(6):452-459.
9. Stempel DA. Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up. Respir Med 2001; 95:992-998.
10. Stempel DA, Meyer JW, Stanford RH, Yancey SW. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol 2001; 107:94-98.
11. Stempel DA, Mauskopf J, McLaughlin T, Yazdani C, Stanford RH. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001; 95:227-234.
12. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002; 109:433-439.
13. Bukstein DA, Henk HJ, Luskin AT. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther 2001; 23(9):1589-1600.
14. Price DB, Ben-Joseph RH, Zhang Q. Changes in asthma drug therapy-costs for patients receiving chronic montelukast therapy in the UK. Respir Med 2001; 95(1):83-89.
15. Edwards LD, Kral KM, Johnson JR, Lincourt WR. A retrospective descriptive medical claims analysis of increased medical risk in asthma management for patients prescribed montelukast compared to fluticasone propionate [abstract 1070]. J Allergy Clin Immunol 2001; 107(2):S329.
16. Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy 2002; 22(2):166-174.
17. Spahn J, Covar R, Stempel DA. Asthma: addressing consistency in results from basic science, clinical trials and observational experience. J Allergy Clin Immunol 2002; 109:S490-S502.
18. Stempel DA, Kelly HW. Approaching value in asthma management: the need to intergrate clinical and economic research with the basic science. J Allergy Clin Immunol 2002; 109:S503-S510.
19. Laumann JM, Bjornson DC. Treatment of Medicaid patients with asthma: comparison with treatment guidelines using disease-based drug utilization review methodology. Ann Pharmacother 1998; 32(12):1290-1294.
20. Balkrishnan R, Christensen DB. A comparison of medication adherence indices to assess long-term inhaled corticosteroid medication use. J Asthma 2001; 38(1):91-98.
21. Balkrishnan R, Byerly WG, Camacho FT, Shrestha A, Anderson RT. Effect of prescription benefit changes on medical care utilization in a Medicare HMO population. Am J Manag Care 2001; 7(11):1093-1100.
22. Stempel DA, Mauskopf J, McLaughlin T, Yazdani C, Stanford RH. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001; 95:227-234.
23. Farber HJ, Capra AM, Finkelstein JA, Lozano P, Quesenberry CP, Jensvold NG, Chi FW, Lieu TA. Misunderstanding of asthma controller medications: association with nonadherence. J Asthma 2003; 40(1):17-25.
24. Balkrishnan R, Christensen DB. Inhaled corticosteroid nonadherence and immediate avoidable medical events in older adults with chronic pulmonary ailments. J Asthma 2000; 37(6):511-517.